Vertex Pharmaceuticals (VRTX) Key Ratios

Stock Card

$540.00

$10.31 (1.95%)

As on 29-Oct-2026 16:14EDT

Market cap

$132,796 Mln

Revenue (TTM)

$12,624 Mln

P/E Ratio

29.9

P/B Ratio

6.5

Div. Yield

0 %

Key Ratios and Highlights

Growth Score (%)	Quarterly		Annual (TTM)
Particulars	QoQ	YoY	1-Year	3-Years	5-Years
Revenue	11.62	12.45	10.56	9.92	13.56
EBIT	11.12	8.20	20.32	6.65	16.39
Net Profit	6.63	6.48	21.10	14.12	17.21
EPS	6.88	7.81	22.80	9.92	17.80
Book Value	--	--	15.70	10.89	17.16

Key Ratios (%)	Average		Annual (TTM)
Particulars	3-Years	5-Years	TTM	Dec-25	Dec-24
EBIT-Margin	28.64	34.16	41.84	38.56	2.53
Net Margin	--	34.08	34.89	--	--
Return on equity	14.13	19.00	22.64	22.54	-3.15
Return on Capital	12.77	17.32	--	19.42	-2.93
Return on Assets	10.53	14.24	14.80	16.24	-2.37
Debt to Equity (x)	--	--	0.00	0.21	0.11

Profitability

View Detailed Peer Comparison

ROCE

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	19.42	-2.93	21.80	25.67	22.64
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROE

22.64

Higher than Peers by 62.36

Profit after tax / Average Net worth * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	22.64	22.54	-3.15	22.99	27.67	24.93
Peer Median	-39.72	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

ROA

14.80

Higher than Peers by 46.06

Profit after tax / Average Total assets * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	14.80	16.24	-2.37	17.71	21.04	18.60
Peer Median	-31.26	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Margin

41.84

Higher than Peers by 118.41

Operating profit (EBIT) / Net Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	41.84	38.56	2.53	44.83	48.01	36.86
Peer Median	-76.58	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Margin

34.89

Higher than Peers by 122.50

Net profit / Total Income (Net sales plus other income) * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	34.89	32.74	-4.86	36.68	37.28	30.88
Peer Median	-87.60	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Profit Margin

(Net profit + Depreciation) / Gross Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	--	--	--	--	--
Peer Median	0.00	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Growth

View Detailed Peer Comparison

Revenue Growth

10.56

Lower than Peers by 48.59

Year on year growth in net sales

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	10.56	0.10	0.12	0.11	0.18	0.22
Peer Median	59.15	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EBIT Growth

20.32

Higher than Peers by 21.79

Year on year growth in operating profit (EBIT)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	20.32	1,568.40	-93.69	3.19	53.56	-12.06
Peer Median	-1.47	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Net Profit Growth

21.10

Higher than Peers by 28.74

Year on year growth in profit after tax

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	21.10	838.09	-114.80	8.96	41.84	-13.63
Peer Median	-7.64	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EPS Growth

22.80

Higher than Peers by 9.44

Year on year growth in earnings per share

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	22.80	8.51	-1.15	0.09	0.40	-0.12
Peer Median	13.36	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Book Value Growth

19.36

Higher than Peers by 28.06

Year on year growth in book value per share

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	19.36	--	--	--	--	--
Peer Median	-8.70	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Solvency

View Detailed Peer Comparison

Debt to Equity

Total debt / Net worth

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	0.21	0.11	0.05	0.06	0.10
Peer Median	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Short term debt to equity ratio

(Short term borrowings / Net worth)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	0.00	0.01	0.00	0.01	0.01
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Current Ratio

3.19

Lower than Peers by 2.71

Current Assets / Current Liabilities and Provisions

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	3.19	2.90	2.69	3.99	4.83	4.46
Peer Median	5.89	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Quick Ratio

2.74

Lower than Peers by 3.02

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	2.74	2.46	2.35	3.78	4.66	4.30
Peer Median	5.75	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Interest Coverage

800.23

Higher than Peers by 802.73

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	800.23	350.11	9.12	100.32	78.23	45.40
Peer Median	-2.51	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

16.91

Lower than Peers by 2.30

Debtors outstanding / Net Sales * 100

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	16.91	17.00	14.60	15.84	16.15	15.01
Peer Median	19.21	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Asset Turnover

0.42

Higher than Peers by 0.36

Sales / Average Total Assets

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	0.42	0.50	0.49	0.48	0.57	0.60
Peer Median	0.06	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Receivable days

Average Debtors / Sales * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	55.39	52.58	55.62	52.74	48.76
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Inventory Days

Average Inventory / Sales * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	292.28	231.99	173.54	137.56	128.03
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Payable days

Average Creditors / Cost of goods sold * 365

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	88.40	92.82	96.77	84.34	70.71
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Cash Conversion Cycle

Receivable Days + Inventory Days - Payable Days

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	259.28	191.75	132.39	105.96	106.07
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Valuation

View Detailed Peer Comparison

Price / Earnings

29.90

Current share price divided by earning per share in the last twelve months

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	29.90	29.37	-195.86	29.33	22.63	24.10
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Price / Book Value

6.46

Higher than Peers by 2.02

Current share price divided by book value per share in the latest financial year

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	6.46	6.22	6.39	6.04	5.40	5.59
Peer Median	4.44	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Dividend Yield

Dividend per share in the past twelve months divided by current share price

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	--	--	--	--	--	--
Peer Median	--	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

EV/EBITDA

24.51

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	24.51	23.30	206.74	20.79	14.72	17.10
Peer Median

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Market Cap

132,796

Higher than Peers by 132,650

Current Share price multiplied by latest total number of shares outstanding

Company Name	TTM	Dec-25	Dec-24	Dec-23	Dec-22	Dec-21	Dec-20	Dec-19	Dec-18	Dec-17	Dec-16
Vertex Pharmaceuticals (VRTX)	132,796	--	--	--	--	--
Peer Median	146	--	--	--	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly